Cargando…
Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date
Potassium-competitive acid blocker (P-CAB) is a class of drug that competitively blocks the potassium-binding site of H(+), K(+)-adenosine triphosphate (ATP)ase. Although the history of this class of drugs started over 30 years ago, clinical use of two P-CABs, revaprazan and vonoprazan, were only re...
Autor principal: | Sugano, Kentaro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784563/ https://www.ncbi.nlm.nih.gov/pubmed/29383028 http://dx.doi.org/10.1177/1756283X17745776 |
Ejemplares similares
-
Potassium-competitive acid blockers and gastroesophageal reflux disease
por: Leowattana, Wattana, et al.
Publicado: (2022) -
Pathophysiology of Potassium-competitive Acid Blocker–refractory Gastroesophageal Reflux and the Potential of Potassium-competitive Acid Blocker Test
por: Masaoka, Tatsuhiro, et al.
Publicado: (2018) -
The Effect of Food on the Pharmacokinetics of the Potassium‐Competitive Acid Blocker Vonoprazan
por: Mulford, Darcy J., et al.
Publicado: (2021) -
Severe Hypomagnesemia Associated with the Long-term Use of the Potassium-competitive Acid Blocker Vonoprazan
por: Okamoto, Masaru, et al.
Publicado: (2021) -
Usefulness of vonoprazan, a potassium ion-competitive acid blocker, for primary eradication of Helicobacter pylori
por: Yamada, Shinya, et al.
Publicado: (2016)